This article is more than 5 years old. Information may no longer be current.

Cumulative HIV viremia may predict AIDS-related lymphoma among patients receiving HAART

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

There may be an independent association between cumulative HIV viremia and risk for lymphoma, according to results of an ongoing German study.

Researchers analyzed data from 6,022 patients in Germany (involving 27,812 patient-years of follow-up) from the Clinical Surveillance of HIV Disease study. The findings were from patients receiving highly-active antiretroviral therapy (HAART) from 1999 to 2006.

The HR for lymphoma among patients with cumulative HIV viremia was 1.67 (95% CI, 1.27-2.20).

The association between HIV viremia and lymphoma varied depending on the lymphoma subtype. The HR for Burkitt-type lymphoma among patients with cumulative HIV viremia was 3.45 (95% CI, 1.52-7.85), whereas there was no association observed for central nervous system lymphoma (HR 1.00; 95% CI, 0.39-2.57).

The only risk factors significantly associated with central nervous system lymphoma included age per 10-year increment (HR 1.83; 95% CI, 1.03-3.24) and cell count <200 cells/mcL (HR 6.53; 95% CI, 1.44-29.51).

The researchers conducted multivariate analyses to determine other risk factors for the development of lymphoma among the patients. These results demonstrated that the HR for age per 10-year increment was 1.42 (95% CI, 1.15-1.75), and that the HR for CD4 cell counts of <200 cells/mcL was 8.16 (95% CI, 3.90-17.10).